Farmasia and Pro Bono Bio have launched Flexiseq in Malaysia, a topically-applied, drug-free gel that provides pain relief, and improved mobility, through nanotechnology. Flexiseq is specially formulated to combat joint pain, in particular that associated with osteoarthritis (OA).
Flexiseq contains Sequessome technology, which consists of nanostructures that cross through the skin barrier after the gel's topical application. On reaching the inside of the joint, the Sequessome nanostructures help to lubricate the joint, reducing pain and increasing mobility. This technology was developed by Pro Bono Bio, an international healthcare company backed by British and Russian expertise and investment.